STUDIES OF PRIMARY IMMUNODEFICIENCY DISEASES
STUDIES OF PRIMARY IMMUNODEFICIENCY DISEASES
批准号:
6288887
负责人:
WARREN STROBER
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
B lymphocyte T lymphocyte biological signal transduction cell cell interaction clinical research gene expression helper T lymphocyte human subject hypogammaglobulinemia immunodeficiency immunogenetics immunoglobulin genes immunopathology leukocyte activation disorder leukopoiesis lymphocyte proliferation protein tyrosine kinase tissue /cell culture
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project 1: During this period we initiated a study of a rare but
immunologically informative primary immunodeficiency disease known as
X-linked hyper-IgM syndrome (XHIM). This disease has recently been
shown to be due to a defect in the gene encoding CD40L, a key T cell
signaling molecule that is essential for interactions between T cells
and B cells or T cells and antigen-presenting cells. It is the role of
CD40L in the T cell-B cell interaction that is responsible for the
obvious immunoglobulin abnormality characterizing the disease.
Activated T cells expressing CD40L and signaling B cells via CD40 is a
necessary antecedent to B cell isotype switching. Hence, in the absence
of CD40L, IgM+ B cells fail to switch to IgG+ and IgA+ B cells and one
observes increased production of IgM and greatly reduced or absent
production of IgG and IgA. For many years, the consequences of failure
to signal via CD40L or T cell function has been largely overlooked in
XHIM. This, despite the fact that CD40L has been shown to be critical
for Th1 T cell differentiation and CTL induction. That a defect in this
area of the immune system may in fact be present in XHIM was suggested
by the observation that patients are prone to certain types of
opportunistic infection and the development of neoplasia. We have
filled in this gap in our knowledge of XHIM by conducting an extensive
series of studies of T cell function in XHIM patients. In initial
studies we determined if patient antigen-presenting cells (APC?s) could
produce IL-12 is stimulated by activated patient T cells, recognizing
that in normals, the latter express CD40L and signal APC?s to produce
this cytokine. We found that, indeed, patient cells stimulated with
either anti-CD3epsilon or PHA plus IFN-gamma induced greatly reduced
IL-12 production as compared to normals. This defect in IL-12
production, however, was not due to an intrinsic inability to produce
IL-12 since direct stimulation of APC?s with LPS plus IFN-gamma or
CD40L-trimer plus IFN-gamma led to normal or even increased IL-12
production. In further studies we probed the consequences of this
reduced IL-12 production and showed that XHIM patient T cells
stimulated by anti-CD3epsilon or PHA produced markedly decreased
amounts of TNF-alpha. In contrast, understimulation in which patients
APC?s were stimulated directly to produce IL-12 by CD40L-trimer and
patient T cell independently stimulated by anti-CD3epsilon, IFN-gamma
production was almost normal. Thus, again, there was no intrinsic
defect of cytokine production. In further studies, we demonstrated that
the above cytokine production defect was accompanied by markedly
reduced T cell maturation in ?memory? CD45RO+ T cells. This defect was
present in both the CD4+ and CD8+ T cell subsets. In studies to explore
the basis of this defect, we showed that normal ?na?ve? CD4+/CD45RA+ T
cells undergo maturation into CD4+/CD45RO+ T cells when stimulated by
SAC, but that this maturation is blocked by the presence of CTLA-Fc, a
substance that interferes with CD28/B7 interactions. It thus becomes
apparent that such maturation depends on signaling of T cells via B7
(CD80 and CD86). Relating this finding in normals to patients with
XHIM, we then showed that patient B cells in PBMC failure to manifest
surface B7 expression when stimulated with PHA, presumably due to lack
of CD40-CD40L interactions. One can therefore conclude that the CD40L
defect in patients leads to T cell immaturity because APC?s fail to
express B7 upon stimulation. Project 2: Studies of the rare syndrome
intestinal lymphangectasia (IL) has been a longstanding interest of
scientists in the Mucosal Immunity Sections as these patients represent
a unique experiment of nature with which to probe immunologic processes
in humans. IL is a primary/congenital or a secondary/acquired disorder
due and generalized but unevenly distributed peripheral abnormalities
of lymphocyte development and a characteric asymmetric edema or a
variety of abnormalities which lead to blockage of lymph flow in the
gastrointestinal tract. Previous studies have revealed that the loss
process in IL is characterized not only by lymphocytopenia, but also by
depletion of lymphocytes in lymphoid tissues and diminished delayed
skin test reactivity. In addition, these studies have shown that
patient T cells manifest poor in vitro proliferative responses to
antigens and mitogens even when T cell numbers are normalized in in
vitro cultures. This implies that a qualitative as well as a
quantitative disorder of T cells is present in IL, on perhaps due to
preferential loss of responsive lymphocyte subpopulations. Evidence in
favor of this possibility has come from studies showing that in IL,
CD4+ T cells are more reduced than CD8+ T cells. In the present study,
we re-examined the question of selective lymphocyte loss in IL
utilizing recently available monoclonal antibodies to identify and
isolate lymphocyte subsets. In the present studies we initially found
that patients with IL have greatly reduced total T cell counts largely
due to reduced CD4+ T cell numbers rather than CD8+ T cell numbers. On
this basis, patients with IL had reversed CD4/CD8 T cell ratios. Of
great interest, the reduced CD4+ T cell levels were due to a selective
decrease in CD45RA+ T cells (na?ve T cells) rather than a decrease in
CD45RO+ T cells which were more or less normal. A similar but lesser
imbalance in the CD8+ T cell CD45RA/RO ratio was also observed. In
addition to these T cell subset abnormalities, patients also had
reduced numbers of B cells (CD20+/CD19+ cells); however, they had
normal numbers of NK cells (CD16+/CD56+ cells). In further studies,
both CD45RA+ and CD45RO+ T cells bearing the CD27 and CD31 markers was
assessed in patients with IL. These markers are associated with more
na?ve T cells that have not undergone extensive prior stimulation. We
found that cells bearing these markers in either the CD45RA+ or CD45RO+
subsets. This again indicates that IL is associated with a selective
decrease in more na?ve T cells. In a final series of studies, we
evaluated the functional capabilities of circulatory cells in IL. Here
we found that patient T cells manifested reduced proliferation when
stimulated by monoclonal antibodies providing polyclonal stimulation
and such reduction persisted even when patient cells were compared with
normal cells of the same subsets. In addition, we found that patient
cells produced less IFN-gamma and IL-2 and more IL-4 and IL-5 than
similarly stimulated control cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of Immune Responses in Humans and Non-Human Primates
-
批准号:6098937
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:WARREN STROBER
-
依托单位:
STUDIES OF PRIMARY IMMUNODEFICIENCY DISEASES
-
批准号:6160653
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:WARREN STROBER
-
依托单位:
Immunoregulation In Humans And Non-human Primates
-
批准号:6985590
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:WARREN STROBER
-
依托单位:
Regulation of T cell Differentiation
-
批准号:7196663
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:WARREN STROBER
-
依托单位:
Immunoregulatory Defects In Inflammatory Bowel Disease
-
批准号:6674046
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:WARREN STROBER
-
依托单位:
Regulation Of Immune Responses In Humans and in Experimental Animals
-
批准号:7592151
-
项目类别:
-
资助金额:$108.73万
-
财政年份:--
-
负责人:WARREN STROBER
-
依托单位:
Regulation of T cell Differentiation
-
批准号:7592251
-
项目类别:
-
资助金额:$118.33万
-
财政年份:--
-
负责人:WARREN STROBER
-
依托单位:
Regulation Of Immune Responses In Humans and in Experime
-
批准号:7299936
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:WARREN STROBER
-
依托单位:
Regulation Of Immune Responses In Humans And Non-human P
-
批准号:6808163
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:WARREN STROBER
-
依托单位:
Regulation Of Immune Responses In Humans and in Experimental Animals
-
批准号:7732455
-
项目类别:
-
资助金额:$79.49万
-
财政年份:--
-
负责人:WARREN STROBER
-
依托单位:
Regulation of T cell Differentiation
-
批准号:7732554
-
项目类别:
-
资助金额:$91.29万
-
财政年份:--
-
负责人:WARREN STROBER
-
依托单位:
Immunoregulatory Defects in Inflammatory Bowel Disease
-
批准号:6431552
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:WARREN STROBER
-
依托单位:
Studies Of Th1/Th2 Differentiation
-
批准号:6521502
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:WARREN STROBER
-
依托单位:
Immunoregulatory Defects In Inflammatory Bowel Disease
-
批准号:7592138
-
项目类别:
-
资助金额:$118.33万
-
财政年份:--
-
负责人:WARREN STROBER
-
依托单位:
Studies Of Th1/th2 Differentiation
-
批准号:6809106
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:WARREN STROBER
-
依托单位:
Immunoregulatory Defects In Inflammatory Bowel Disease
-
批准号:7732442
-
项目类别:
-
资助金额:$91.29万
-
财政年份:--
-
负责人:WARREN STROBER
-
依托单位:
Studies of Primary Immunodeficiency Diseases
-
批准号:6431601
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:WARREN STROBER
-
依托单位:
Immunoregulatory Defects in Inflammatory Bowel Disease
-
批准号:6098921
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:WARREN STROBER
-
依托单位:
Immunoregulatory Defects In Inflammatory Bowel Disease
-
批准号:6985228
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:WARREN STROBER
-
依托单位:
Regulation Of Immune Responses In Humans And Non-human P
-
批准号:6674047
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:WARREN STROBER
-
依托单位:
海外基金